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Abstract
Introduction and Objective. The ability to perceive the symptoms of hypoglycemia during the early decrease in plasma 
glucose concentration may be critical for the safety of T1DM patients treated with intensive insulin therapy, including those 
treated with continuous subcutaneous insulin infusion (CSII). In the presented observational study an attempt was made 
to asses clinical factors that might affect subjective awareness of hypoglycemia in CSII-treated T1DM patients, with special 
attention to factors specific for this mode of treatment.
Materials and Methods. For the purpose of the study, data of 110 CSII-treated T1DM patients were collected (78 females 
and 32 males). The records were analyzed from glucose meters (200-300 measurements/download, depending on meter 
type) and insulin pumps (total insulin dose, basal/bolus ratio, number of boluses/day, bolus calculator and dual wave/square 
bolus usage, continuous glucose monitoring data) from the last 3 years.
Results. It was found that the level of subjective hypoglycemia perception inversely correlated with the number of 
hypoglycemic episodes per 100 measurements, age, duration of diabetes, time on insulin pump, and positively correlated 
with mean glycemia (n =  98; r = 0.22; p = 0.0286). With respect to CSII-related factors, hypoglycemia perception inversely 
correlated with the percentage of basal insulin (n = 106; r = -0.20; p = 0.0354). In stepwise regression analysis, independent 
predictors for impaired hypoglycemia perception were: age β = -0.29 (p = 0.023), duration of diabetes β = -0.24 (p = 0.029) 
and number of the hypoglycemia episodes for 100 measurements β = -0.33 (p = 0.0005).
Conclusions. Risk factors for impaired hypoglycemia perception in CSII-treated patients include those identified previously 
for the general population of T1DM individuals. In addition, the presented results suggest that a higher basal/bolus ratio 
may lead to impairment of the ability to perceive early symptoms of hypoglycemia.
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IntROduCtIOn
The Diabetes Control and Complications Trial (DCCT) 
showed that intensive insulin therapy in type 1 diabetes 
(T1D) combined with structured self-monitoring of blood 
glucose can delay the onset and slow down the progression 
of the microvascular complications of diabetes, compared 
to the conventional therapy [1]. Unfortunately, it has been 
shown that intensive insulin therapy may increase the risk 
of hypoglycemia [1, 2, 3], which is a major limiting factor in 
the management of diabetes.
The ability to perceive symptoms of hypoglycemia during 
the early decrease in plasma glucose concentrations, called 
hypoglycemia awareness, may be critical for the patient’s 
safety and the prevention of severe hypoglycemic episodes, 
irrespective of the treatment mode [4]. Furthermore, impaired 
hypoglycemia perception may lead to hypoglycemia fear, 
which may result in behaviours purposefully elevating the 
patients’ blood glucose levels [5]. It may also severely limit 
the patient’s activities, as well as employment options [6].
Intensive insulin therapy may be implemented either 
with continuous subcutaneous insulin infusion (CSII) 
via a personal pump, or with a multiple daily injections 
(MDI) model. The currently available data suggest that 
in adults with T1D, CSII is more effective than MDI in 
optimizing glycemic control [7, 8, 9]. CSII was shown not 
only to prevent hypoglycemic episodes, but also to improve 
hypoglycemia awareness [10], especially if combined with 
proper education [11].
Irrespective of the mode of treatment, there are several 
well-defined factors influencing hypoglycemia awareness 
or perception. It was shown that avoidance of exposure 
to hypoglycemia can restore hypoglycemia awareness [12, 
13], even brief and relatively rare episodes of hypoglycemia 
reduce the detection rate of clinical hypoglycemia in T1DM 
individuals [14]. Other risk factors for impaired low glucose 
perception include C-peptide negativity, male gender, and 
long diabetes duration [15]. Diabetic autonomic neuropathy 
causes many of the counter-regulatory defects found in 
patients with hypoglycemia unawareness [16].
Unfortunately, there are very few data concerning 
factors that may affect hypoglycemia perception among 
patients treated with personal insulin pumps. Usage of 
rapid acting analogs during CSII therapy in individuals 
with hypoglycemia unawareness results in better clinical 
outcomes in comparison to regular short acting insulin 
based treatment [17]. However, these data are clinically 
obsolete, since regular human insulin is hardly ever used in 
CSII [7, 8, 9]. Other CSII-specific factors that may influence 
hypoglycemia perception remain to be identified.
Address for correspondence: Tomasz Klupa, Department and Chair of Metabolic 
Diseases, Kopernika 15, Jagiellonian University, 31-501, Kraków, Poland
E-mail: tomasz.klupa@uj.edu.pl
Received: 27 September 2012; accepted: 27 December 2012
Annals of Agricultural and Environmental Medicine 2013, Vol 20, No 1
Bartłomiej Matejko, Małgorzata Grzanka, Beata Kieć-Wilk, Maciej T. Malecki, Tomasz Klupa. Clinical factors affecting the perception of hypoglycemia in type 1 diabetes…
Aim of the study. In this observational study, an attempt 
was made to asses clinical factors that might affect subjective 
awareness of hypoglycemia in CSII-treated T1DM patients, 
with special attention to factors specific for this mode of 
treatment.
MAteRIAl And MethOds
For the purpose of the study, data of 110 CSII treated 
T1DM patients were collected (78 females and 32 males). 
Demographic (gender, age), anthropometric measures 
(BMI), diabetes-related variables (complications, diabetes 
duration, insulin pump therapy duration and HbA1C values) 
were obtained from the patients’ clinical files. Patients with 
advanced microvascular complications of diabetes were 
excluded from the study. Records were analyzed from glucose 
meter and insulin pump from the last 3 years. As for glucose 
meters, during each visit, 200-300 measurements/download 
were obtained, depending on meter type. These data were 
used to calculate glycemia statistics and the number of 
hypoglycemic events (defined as glucose levels below 
55 mg/dL or 3.0 mmol/l) per 100 measurements. Insulin 
pump data were downloaded regularly during each visit via 
the Carelink Professional or AccuChek Smart Pix software. 
In the search for factors that could influence hypoglycemia 
perception, data were analyzed concerning total insulin dose, 
basal/bolus ratio, number of boluses/day, bolus calculator 
and dual wave/square bolus usage, and continuous glucose 
monitoring data. Individuals included into the study 
completed a questionnaire concerning the level of glucose 
at which they perceive symptoms of hypoglycemia. On this 
basis, they were divided into 3 subgroups (1st<50 mg/dl, 
2nd (50-70 mg/dl), 3rd(≥70 mg/dl). As for statistical analysis, 
data were presented as the number of cases, mean or 
percentage. Normality was tested with the W Shapiro-Wilk 
test. The correlation ‘r’ coefficient (R Spearman) was used to 
analyze the relation between the several variables studied, 
with significance level of 5% (p<0.05). Differences in outcomes 
were evaluated by using one-way analysis of variance ANOVA 
or the Kruskal–Wallis test (non-parametric ANOVA). 
Multivariate linear regression with stepwise selection using 
a p value of <0.05 as the threshold for adding a variable was 
used to determine predictors of impaired hypoglycemia 
perception. All p values are two-sided. All the statistical 
procedures were performed using the Statistica program for 
Windows by StatSoft, Inc., version 10.
Results
It was found that the level of subjective hypoglycemia 
perception inversely correlated with the number of 
hypoglycemic episodes per 100 measurements (n = 100, 
r = -0.34, p = 0.0006), age (n = 110; r = -0.26; p = 0.0050), 
duration of diabetes (n = 110; r = -0.19; p = 0.0409), time on 
insulin pump (n = 110; r = -0.19; p = 0.0447), and positively 
correlated with mean glycemia (n = 98; r = 0.22; p = 0.0286). 
There was no evidence of correlation with HbA1c level 
(p = 0.0836), BMI (p = 0.9805), number of blood glucose 
measurements per day (p = 0.6501), daily insulin dose 
(p = 0.5514), insulin units per kg of body weight (p = 0.7863) 
and number of boluses per day (p = 0.8425).
With respect to CSII-related factors, hypoglycemia 
perception inversely correlated with percent of basal insulin 
(n = 106; r = -0.20; p = 0.0354) (Tab. 1). Usage of pump tools, 
such as a bolus calculator, dual wave boluses or CGMS, had no 
impact on hypoglycemia perception (Tab. 2). For the purpose 
of the multivariate analysis, 8 variables were included in 
the multivariate model (6 variables for which statistical 
significance was obtained in the correlation analysis, and per 
force HbA1c and gender). Eight cases, for which the distance 
of Cook was greater than 2.5, were removed from the analysis. 
An essential predictive model of hypoglycemia perception 
was created (p<0.0000). The assumptions of the analysis were 
fulfilled. In stepwise regression analysis, the independent 
predictors for impaired hypoglycemia perception were: 
age β = -0.29 (p = 0.023), duration of diabetes β = -0.24 
(p = 0.029) and number of the hypoglycemia episodes for 100 
measurements β = -0.33 (p = 0.0005). This model, however, 
enabled only 29% of variation of studied parameter (R2 = 29) 
to be explained. No other independent variables achieved 
nominal statistical significance in the multivariate model 
of impaired hyperglycemia perception.
dIsCussIOn
The presented study confirms the findings of previous 
analyses that hypoglycemia perception may be affected by the 
frequency of hypoglycemic episodes per 100 measurements, 
mean glycemia, age, duration of diabetes [12, 13, 14, 15]. Since 
CSII- treated patients were analyzed, an attempt was also 
made to identify factors that may influence hypoglycemia 
perception and are specific for this mode of treatment. 
An inverse correlation was found between hypoglycemia 
perception and the percentage of basal insulin in the total daily 
insulin dose during CSII therapy. However, it was not possible 
to confirm this finding in the multivariate analysis, perhaps 
due to the relatively small number of patients in the studied 
groups. As little as one third of variation of the parameter 
with multivariate analysis could be explained, which means 
that hypoglycemia perception is probably multifactorial, and 
some of the factors affecting it remain to be identified.
It can be speculated that a higher basal insulin dose 
may lead to more frequent hypoglycemia, and thus impair 
hypoglycemia perception. Such a correlation between the 
basal/bolus insulin ratio and the risk of hypoglycemia has 
been shown previously by Blasetti et al. [18]; however, the 
table 1. Correlation of clinical variables with hypoglycemia perception.
Pairs of variables: hypoglycaemia perception vs. N R Spearman p
HbA1c 107 0.17 0.0836
Age 110 -0.26 0.0050
Duration of diabetes 110 -0.19 0.0409
Time on insulin pump 110 -0.19 0.0447
BMI 107 0.00 0.9805
Mean glycaemia  98 0.22 0.0286
Number of blood glucose measurements per day  98 -0.05 0.6501
Daily insulin dose 105 -0.06 0.5514
Insulin units per kg of body weight 106 -0.02 0.7863
Percent of basal insulin 106 -0.20 0.0354
No. of boluses per day 105 0.02 0.8425
No. of hypoglycemic episodes per 100 measurements 100 -0.34 0.0006
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problem of hypoglycemia perception itself, contrary to the 
presented analysis, was not addressed. It was shown that the 
optimal basal/bolus ratio is age-dependent, but for young 
adult individuals the percentage of basal insulin should be 
generally around 40% or less [19]. This is also true for older 
patients with T1DM [20].
COnClusIOn
To summarize, risk factors for impaired hypoglycemia 
perception in CSII treated patients include those identified 
previously for the general population of T1DM individuals. 
As for modifiable CSII-specific factors, the presented results 
suggest that a higher basal/bolus ratio may lead to impairment 
of the ability to perceive early symptoms of hypoglycemia.
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table 2. Patient characteristics in three groups divided according to 
level of subjective hypoglycaemia perception (<50 mg/dl, 50-70 mg/dl, 
≥70 mg/dl) and results of Anova and post-hoc tests
Variable <50 mg/dl
N = 14
[50-70 mg/dl
N = 73
> = 70 mg/dl
N = 23
Mean 
[xśr]
p
HbA1c [%] 6.90 7.27 7.43 7.25 0.3352
Gender
F [n] 11
3
52
21
15
8
- 0.6827
M [n]
Age [y] 34.8 26.7 24.2 27.2 0.0140*
BMI [kg/m2] 24.2 22.9 23.6 23.2 0.0803
Diabetes duration 
[y]
15.8 13.2 10.1 12.9 0.1224
Time on CSII [y] 4.9 4.5 3.4 4.3 0.1088
Mean glycaemia 
[mg/dl]
136.8 150.2 155.7 149.7 0.0760
Blood glucose 
measurements 
per day [n]
6.9 5.7 6.0 5.9 0.2897
No. of boluses per 
day  [n]
6.2 5.8 6.0 5.9 0.4110
Daily insulin dose 
[Iu]
46.3 46.6 45.0 46.2 0.6788
Percentage of 
basal insulin [%]
42.6 40.8 36.5 40.1 0.0819
Insulin unit per kg 
of weight [Iu/kg]
0.69 0.71 0.69 0.70 0.6939
Hypoglycaemia 
episodes per 100 
measurement [n]
7.6 5.9 3.2 5.5 0.0028**
Dual Wave 
Bolus/ 
Square 
Bolus [n]
Use
2
11
10
61
2
21
- 0.7734Do 
not 
use
CGMS [n]
Use
5
8
15
55
3
20
- 0.2052Do 
not 
use
Bolus 
Calculator 
[n]
Use
7
6
39
31
8
15
- 0.2138Do 
not 
use
p values for ANOVA analysis of differences among studied groups.
For post hoc analysis (Scheffe’s Test): 
* – Group 1 vs. Group 3 (p = 0.0111)
** – Group 3 vs. Group 1 (p = 0.0073) and vs. Group 2 (p = 0.0099)
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